Kailera Therapeutics (KLRA) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Syndax Pharmaceuticals is the larger company by market cap ($1.52 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KLRA | SNDX |
|---|---|---|
| Share price | $11.61 | $16.99 |
| Market cap | $1.51B | $1.52B |
| 1-day change | +16.10% | +0.53% |
| YTD return | — | -19.13% |
| 1-year return | — | +4.88% |
| 5-year return | — | -8.61% |
| EPS (TTM) | $-5.25 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | — | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $28.23 | $25.59 |
| 52-week low | $9.76 | $12.99 |
| Distance from 52-week high | -58.87% | -33.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +265.20% | +121.01% |
| Average volume | 865.82K | 1.54M |
| Shares outstanding | 129.64M | 89.30M |
| Employees | 145 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kailera Therapeutics
KLRA stock →Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
KLRA vs SNDX FAQ
Which is bigger, Kailera Therapeutics or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $1.52B compared with $1.51B for Kailera Therapeutics (KLRA).
Are Kailera Therapeutics and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.